Latest News and Press Releases

The preclinical study proves that a single intratumoral injection of a NanoZolid® formulated STING-agonist has equal or better efficacy compared to multiple injections of a standard STING-agonist...

LIDDS has agreed to transfer the licensing agreement for Liproca® Depot in China to Jiangxi Puheng Pharmaceuticals Ltd following a request from the owners of Jiangsu Ambition Medical. The change of...

   The international Journal of Drug Delivery Science and Technologywill publish the scientific article in the August edition titled "Cold isostatic pressing of hydrating calcium sulfate as a means...

LIDDS AB (publ) has decided on a direct share issue to Nyenburgh Holding BV, AESCAP 2.0 and BWG Invest, all being international funds that invests in closely selected European biotech- and pharma...

The European patent office has approved LIDDS' patent related to devices and methods of injection. The patent is now approved in all major markets and provides protection for all drug formulations...

Den 16 maj 2018 hölls årsstämma i LIDDS AB (publ). Nedan följer sammanfattning av de beslut som fattades. Beslut fattades med erforderlig majoritet. Vid stämman var 2 418 048  (11,1 %) av totalt...

UPPSALA, SWEDEN - LIDDS AB (publ) has signed a license agreement for Liproca® Depot with Jiangsu Ambition Medical, a Chinese pharmaceutical company specializing in global collaborations and...

FÖRSTA KVARTALET: JANUARI - MARS 2018 Nettoomsättningen uppgick till 0,0 (0,0) KSEK Kostnaderna uppgick till 2,0 (1,8) MSEK Resultatet före och efter skatt uppgick till -2,0 (-1,8) MSEK ...

UPPSALA, SWEDEN - LIDDS AB (publ) is today unveiling new animal data which demonstrates that subcutaneously injected NanoZolid® can act as a depot for systemic delivery of pharmaceutically active...

För mer information, vänligen kontakta: Monica Wallter, CEO, +46 (0)737 07 09 22, monica.wallter@liddspharma.comBengt Norvik, CFO, +46 (0)730 74 68 00, bengt.norvik@liddspharma.com LIDDS utvecklar...